Journal profile · Respiratory System
Lung Cancer
ISSN 0169-5002 · eISSN 1872-8332 · Elsevier Ireland Ltd · NETHERLANDS · Monthly · Founded 1985
Lung Cancer: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.14; hybrid open access; APC about USD 3,390; median 79 days to acceptance (106 articles, last 24 months); community-reported acceptance: fairly hard; 851 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Lung Cancer is published by Elsevier Ireland Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment and Lung Cancer Research Studies, together about 57.6% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Browse through a wide range of high-quality academic journals offered by Elsevier, including open access options, to enrich your research journey.
From the journal's Aims & Scope
Research area (LetPub): Respiratory System
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine23.9%
- Lung Cancer Diagnosis and TreatmentMedicine18.9%
- Lung Cancer Research StudiesMedicine14.8%
- Neuroendocrine Tumor Research AdvancesMedicine4.4%
- Radiomics and Machine Learning in Medical ImagingMedicine3.4%
- Occupational and environmental lung diseasesMedicine3.3%
- Cancer Immunotherapy and BiomarkersMedicine3%
- Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Respiratory System | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.14LetPub ·
- CiteScore 2026-06
- 7.4LetPub ·
- SJR 2026-06
- 1.93LetPub ·
- SNIP 2026-06
- 1.41LetPub ·
- h-index
- 114LetPub ·
- h-index
- 188OpenAlex ·
- i10-index
- 6,571OpenAlex ·
- 2-year mean citedness
- 1.68OpenAlex ·
- Self-citation rate
- 3.8%LetPub ·
- Share of gold OA articles
- 30.75%LetPub ·
Volume
- Articles per year
- 320LetPub ·
Articles by year OpenAlex count · 27,536 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 598 | 136 | 113 |
| 2025 | 851 | 205 | 1,165 |
| 2024 | 614 | 153 | 2,195 |
| 2023 | 600 | 154 | 3,273 |
| 2022 | 426 | 150 | 4,222 |
| 2021 | 605 | 186 | 6,683 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
79 daysMedian, submission to acceptance · P25–P75 52 days – 114 days
- Acceptance to online
- median 1 days (106 articles)
- Submission to online
- median 80 days
- Sample
- 106 articles with submission and acceptance dates (718 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,390 / EUR 3,170 / GBP 2,710 / JPY 420,460 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Elsevier Ireland Ltd
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Monthly
- Founded
- 1985
- ISSN
- 0169-5002
- Electronic ISSN
- 1872-8332
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Lung Cancer
What CAS zone is Lung Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Lung Cancer is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology / Respiratory System. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Lung Cancer?
The latest impact factor listed by LetPub is 5.14; CiteScore 7.4, h-index 188.
How long does peer review take at Lung Cancer?
Based on the dates recorded on 106 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 79 days (interquartile range 52–114 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Lung Cancer?
According to LetPub and DOAJ records, Lung Cancer is indexed in SCIE and Scopus.
Is Lung Cancer open access, and what is the APC?
Lung Cancer is a hybrid journal. For open-access publication: APC about USD 3,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .